Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.33 |
| ▸ | PAK4 | O96013 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15743897 | 0.82 | BRD4 (0.48) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL4098266 | 0.81 | BRD4 (0.32) | BRD4 | |
| SCHEMBL18307127 | 0.81 | BRD4 (0.47) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL13181117 | 0.81 | BRD4 (0.47) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL2843728 | 0.78 | BRD4 (0.31) | BRD4 | |
| SCHEMBL2843725 | 0.78 | BRD4 (0.31) | BRD4 | |
| SCHEMBL13657928 | 0.78 | BRD4 (0.48) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL13661740 | 0.78 | BRD4 (0.46) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL16941382 | 0.78 | BRD4 (0.46) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL2840423 | 0.77 | AKR1B1 (0.34) | BRD4NPC1HSD17B10NTRK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922247-A1 | 15-PGDH INHIBITOR | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020145250-A1 | 15-PGDH INHIBITOR | 杏林製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2015071780-A1 | ALKYLIDINE SUBSTITUTED HETEROCYCLYL DERIVATIVES AS ANTI-BACTERIAL AGENTS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-05-21 | — | — | WO | disclosed |
| EP-2848614-A2 | Acrylamide derivatives as antibiotic agents | Debiopharm International SA (CH) | 2015-03-18 | — | — | EP | disclosed |
| EP-2848614-A2 | Acrylamide derivatives as antibiotic agents | Debiopharm International SA (CH) | 2015-03-18 | — | — | EP | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | BRD4 168/4885KDM4E 3209/4885ALDH1A1 2669/4885 |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | BRD4 2556/4885KDM4E 4494/4885ALDH1A1 2015/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | BRD4 315/4885KDM4E 4426/4885ALDH1A1 1379/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | BRD4 504/4885KDM4E 4139/4885ALDH1A1 4188/4885 |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | BRD4 203/4885KDM4E 2881/4885ALDH1A1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.